ARS Pharmaceuticals (SPRY) Equity Average (2020 - 2026)

ARS Pharmaceuticals has disclosed Equity Average across 7 years of filings, most recently posting $87.8 million for Q1 2026.

• Equity Average for Q1 2026 came in at $87.8 million, down 63.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.8 million (down 63.86% YoY), and the FY2025 annual result was $185.5 million, down 23.9% from the prior year.
• Equity Average came in at $87.8 million for Q1 2026 at ARS Pharmaceuticals, down from $131.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $267.0 million in Q1 2023 to a low of -$47.1 million in Q3 2022.
• The 5-year median for Equity Average is $210.6 million (2025), against an average of $159.6 million.
• Across the five-year window, Equity Average sank 119.61% in 2022 and surged 868.14% in 2023, its largest moves.
• ARS Pharmaceuticals' Equity Average stood at $111.4 million in 2022, then surged by 110.14% to $234.0 million in 2023, then slipped by 2.19% to $228.9 million in 2024, then sank by 42.79% to $131.0 million in 2025, then slumped by 32.97% to $87.8 million in 2026.
• The last three Equity Average figures came in at $87.8 million (Q1 2026), $131.0 million (Q4 2025), and $170.0 million (Q3 2025), per Business Quant data.